Omalizumab facilitates rapid oral desensitization for peanut allergy

BACKGROUND: Peanut oral immunotherapy (OIT) is a promising approach to peanut allergy but reactions are frequent and some patients cannot be desensitized. The anti-IgE medication omalizumab (Xolair) may allow more rapid peanut updosing and decrease reactions. OBJECTIVE: To evaluate if omalizumab fac...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Allergy Clin Immunol
Hauptverfasser: MacGinnitie, Andrew J., Rachid, Rima, Gragg, Hana, Little, Sara V, Lakin, Paul, Cianferoni, Antonella, Heimall, Jennifer, Makhija, Melanie, Robison, Rachel, Chinthrajah, R. Sharon, Lee, John, Lebovidge, Jennifer, Dominguez, Tina, Rooney, Courtney, Lewis, Megan Ott, Koss, Jennifer, Burke-Roberts, Elizabeth, Chin, Kimberly, Logvinenko, Tanya, Pongracic, Jacqueline A., Umetsu, Dale T., Spergel, Jonathan, Nadeau, Kari C., Schneider, Lynda C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2016
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5369605/
https://ncbi.nlm.nih.gov/pubmed/27609658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaci.2016.08.010
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge